Published Date:2024-08-12 Original Link:https://www.onenessbio.com/en/news_detail312_2.htm No 3 Date of announcement 2024/08/12 Time of announcement 16:34:05 Subject Announcement of change to the financial officer, accounting officer, acting spokesperson and corporate governance officer of the company. To which item it meets paragraph 8 Date of events 2024/08/12 Statement Type of personnel changed (please enter: spokesperson, acting spokesperson, important...Read More
Published Date:2024-08-12 Original Link:https://www.onenessbio.com/en/news_detail311_2.htm No 2 Date of announcement 2024/08/12 Time of announcement 16:29:17 Subject Oneness announces the resolution of the Board of Directors on the Record Date of Capital Increase for the issuance of Restricted Employee Shares in 2023. To which item it meets paragraph 53 Date of events 2024/08/12 Statement Date of occurrence...Read More
Published Date:2024-08-12 Original Link:https://www.onenessbio.com/en/news_detail310_2.htm No 1 Date of announcement 2024/08/12 Time of announcement 16:24:34 Subject The Company’s 2024Q2 consolidated financial statements have been approved by the Board of Directors To which item it meets paragraph 31 Date of events 2024/08/12 Statement Date of the board of directors submitted or approved: 2024/08/12 Date of the audit...Read More
Published Date:2024-08-07 Original Link:https://www.onenessbio.com/en/news_detail309_2.htm No 1 Date of announcement 2024/08/07 Time of announcement 20:05:43 Subject Fespixon has passed the preliminary review by the National Healthcare Security Administration of China To which item it meets paragraph 53 Date of events 2024/08/07 Statement Date of occurrence of the event: 2024/08/07 Company name: ONENESS BIOTECH CO., LTD. Relationship...Read More
Published Date:2024-08-06 Original Link:https://www.onenessbio.com/en/news_detail308_2.htm No 1 Date of announcement 2024/08/06 Time of announcement 21:25:12 Subject Fespixon, the new drug in treatment of diabetic foot ulcers has been approved by Indonesia BPOM and the drug license will be collected To which item it meets paragraph 10 Date of events 2024/08/06 Statement Date of occurrence of the...Read More
Published Date:2024-08-02 Original Link:https://www.onenessbio.com/en/news_detail307_2.htm No 1 Date of announcement 2024/08/02 Time of announcement 17:21:12 Subject Announcement of the date of the Company’s board of directors meeting for the Second Quarter of 2024 Consolidated Financial Reports To which item it meets paragraph 31 Date of events 2024/08/02 Statement Date of a notice of the board of...Read More
Published Date:2024-07-25 Original Link:https://www.onenessbio.com/en/news_detail306_2.htm No 1 Date of announcement 2024/07/25 Time of announcement 19:37:02 Subject Fespixon has been included in CSE Expert consensus on wound treatment of diabetic foot ulcer (2024). The health economics analysis supports its cost-effectiveness. To which item it meets paragraph 53 Date of events 2024/07/25 Statement Date of occurrence of the...Read More
Published Date:2024-07-22 Original Link:https://www.onenessbio.com/en/news_detail305_2.htm No 1 Date of announcement 2024/07/22 Time of announcement 20:44:43 Subject The EU MDR application of Bonvadis for acute and chronic wounds and scar management has been accepted by EU Notified Body for QMS and product certification. To which item it meets paragraph 10 Date of events 2024/07/22 Statement Date of...Read More
Published Date:2024-07-21 Original Link:https://www.onenessbio.com/en/news_detail304_2.htm No 1 Date of announcement 2024/07/21 Time of announcement 22:40:52 Subject Oneness and Microbio (Shanghai) have entered into an exclusive agreement of Fespixon commercialization with China Resources Double Crane Pharmaceutical Co., Ltd. To which item it meets paragraph 10 Date of events 2024/07/19 Statement Date of occurrence of the event: 2024/07/19...Read More
